Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein

Chih Hsin Yang, Ching Ju Huang, Chao Shun Yang, Yu Chuan Chu, Ann Lii Cheng, Jacqueline Whang-Peng, Pan Chyr Yang

Research output: Contribution to journalArticle

84 Citations (Scopus)

Abstract

Gefitinib inhibits the ATP-binding site of the tyrosine kinase associated with the epidermal growth factor receptor. It is conceivable that gefitinib may inhibit functions of ATP-binding cassette (ABC) transporters by binding at their ATP-binding sites. The aim of this study is to systematically explore the combined effect of gefitinib and chemotherapeutic agents in gefitinib- insensitive multidrug resistant (MDR) cells that overexpress ABC transporters. MCF7 breast carcinoma cells and CLI lung adenocarcinoma cells were both insensitive to gefitinib. MDR cancer cells were developed by stepwise escalating concentrations of each chemotherapeutic agent in culture media. Cells that overexpress P-glycoprotein (MCF7/Adr and CLI/Pac), breast cancer-resistant protein (MCF7/TPT and CLI/Tpt), and MDR-associated protein 1 (MCF7/Vp) were used in this study. All resistant mutants were insensitive to gefitinib. Gefitinib (0.3-3 μmol/L) added to culture media had no effect on IC50 values of paclitaxel, topotecan, doxorubicin, or etoposide in wild-type MCF7 or CLI cells. In contrast, these concentrations of gefitinib caused a dose-dependent reversal of resistance to paclitaxel in CLI/Pac cells, to doxorubicin in MCF7/ADR cells, and to topotecan in CLI/Tpt and MCF7/TPT cells. Gefitinib had no influence on sensitivity to etoposide in MDR-associated protein1 overexpressing MCF7/VP cells. Topotecan efflux was inhibited and accumulation was partially restored in CLI/Tpt and MCF7/TPT cells when cells were incubated simultaneously with gefitinib. Our results suggest that the interaction of gefitinib and chemotherapeutic agents does occur in cells expressing one of these two proteins.

Original languageEnglish
Pages (from-to)6943-6949
Number of pages7
JournalCancer Research
Volume65
Issue number15
DOIs
Publication statusPublished - Aug 1 2005
Externally publishedYes

Fingerprint

Adenosine Triphosphate
Drug Therapy
Neoplasms
Proteins
MCF-7 Cells
Topotecan
ATP-Binding Cassette Transporters
Etoposide
Paclitaxel
Doxorubicin
Culture Media
gefitinib
Binding Sites
Breast Neoplasms
P-Glycoprotein
Epidermal Growth Factor Receptor
Protein-Tyrosine Kinases
Inhibitory Concentration 50
9 alpha,11 alpha,15 alpha-trihydroxy-16-phenoxy-17,18,19,20-tetranorprosta-4,5,13-trienoic acid

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein. / Yang, Chih Hsin; Huang, Ching Ju; Yang, Chao Shun; Chu, Yu Chuan; Cheng, Ann Lii; Whang-Peng, Jacqueline; Yang, Pan Chyr.

In: Cancer Research, Vol. 65, No. 15, 01.08.2005, p. 6943-6949.

Research output: Contribution to journalArticle

Yang, Chih Hsin ; Huang, Ching Ju ; Yang, Chao Shun ; Chu, Yu Chuan ; Cheng, Ann Lii ; Whang-Peng, Jacqueline ; Yang, Pan Chyr. / Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein. In: Cancer Research. 2005 ; Vol. 65, No. 15. pp. 6943-6949.
@article{c72832c9688e493cb6d384d207ebd027,
title = "Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein",
abstract = "Gefitinib inhibits the ATP-binding site of the tyrosine kinase associated with the epidermal growth factor receptor. It is conceivable that gefitinib may inhibit functions of ATP-binding cassette (ABC) transporters by binding at their ATP-binding sites. The aim of this study is to systematically explore the combined effect of gefitinib and chemotherapeutic agents in gefitinib- insensitive multidrug resistant (MDR) cells that overexpress ABC transporters. MCF7 breast carcinoma cells and CLI lung adenocarcinoma cells were both insensitive to gefitinib. MDR cancer cells were developed by stepwise escalating concentrations of each chemotherapeutic agent in culture media. Cells that overexpress P-glycoprotein (MCF7/Adr and CLI/Pac), breast cancer-resistant protein (MCF7/TPT and CLI/Tpt), and MDR-associated protein 1 (MCF7/Vp) were used in this study. All resistant mutants were insensitive to gefitinib. Gefitinib (0.3-3 μmol/L) added to culture media had no effect on IC50 values of paclitaxel, topotecan, doxorubicin, or etoposide in wild-type MCF7 or CLI cells. In contrast, these concentrations of gefitinib caused a dose-dependent reversal of resistance to paclitaxel in CLI/Pac cells, to doxorubicin in MCF7/ADR cells, and to topotecan in CLI/Tpt and MCF7/TPT cells. Gefitinib had no influence on sensitivity to etoposide in MDR-associated protein1 overexpressing MCF7/VP cells. Topotecan efflux was inhibited and accumulation was partially restored in CLI/Tpt and MCF7/TPT cells when cells were incubated simultaneously with gefitinib. Our results suggest that the interaction of gefitinib and chemotherapeutic agents does occur in cells expressing one of these two proteins.",
author = "Yang, {Chih Hsin} and Huang, {Ching Ju} and Yang, {Chao Shun} and Chu, {Yu Chuan} and Cheng, {Ann Lii} and Jacqueline Whang-Peng and Yang, {Pan Chyr}",
year = "2005",
month = "8",
day = "1",
doi = "10.1158/0008-5472.CAN-05-0641",
language = "English",
volume = "65",
pages = "6943--6949",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "15",

}

TY - JOUR

T1 - Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein

AU - Yang, Chih Hsin

AU - Huang, Ching Ju

AU - Yang, Chao Shun

AU - Chu, Yu Chuan

AU - Cheng, Ann Lii

AU - Whang-Peng, Jacqueline

AU - Yang, Pan Chyr

PY - 2005/8/1

Y1 - 2005/8/1

N2 - Gefitinib inhibits the ATP-binding site of the tyrosine kinase associated with the epidermal growth factor receptor. It is conceivable that gefitinib may inhibit functions of ATP-binding cassette (ABC) transporters by binding at their ATP-binding sites. The aim of this study is to systematically explore the combined effect of gefitinib and chemotherapeutic agents in gefitinib- insensitive multidrug resistant (MDR) cells that overexpress ABC transporters. MCF7 breast carcinoma cells and CLI lung adenocarcinoma cells were both insensitive to gefitinib. MDR cancer cells were developed by stepwise escalating concentrations of each chemotherapeutic agent in culture media. Cells that overexpress P-glycoprotein (MCF7/Adr and CLI/Pac), breast cancer-resistant protein (MCF7/TPT and CLI/Tpt), and MDR-associated protein 1 (MCF7/Vp) were used in this study. All resistant mutants were insensitive to gefitinib. Gefitinib (0.3-3 μmol/L) added to culture media had no effect on IC50 values of paclitaxel, topotecan, doxorubicin, or etoposide in wild-type MCF7 or CLI cells. In contrast, these concentrations of gefitinib caused a dose-dependent reversal of resistance to paclitaxel in CLI/Pac cells, to doxorubicin in MCF7/ADR cells, and to topotecan in CLI/Tpt and MCF7/TPT cells. Gefitinib had no influence on sensitivity to etoposide in MDR-associated protein1 overexpressing MCF7/VP cells. Topotecan efflux was inhibited and accumulation was partially restored in CLI/Tpt and MCF7/TPT cells when cells were incubated simultaneously with gefitinib. Our results suggest that the interaction of gefitinib and chemotherapeutic agents does occur in cells expressing one of these two proteins.

AB - Gefitinib inhibits the ATP-binding site of the tyrosine kinase associated with the epidermal growth factor receptor. It is conceivable that gefitinib may inhibit functions of ATP-binding cassette (ABC) transporters by binding at their ATP-binding sites. The aim of this study is to systematically explore the combined effect of gefitinib and chemotherapeutic agents in gefitinib- insensitive multidrug resistant (MDR) cells that overexpress ABC transporters. MCF7 breast carcinoma cells and CLI lung adenocarcinoma cells were both insensitive to gefitinib. MDR cancer cells were developed by stepwise escalating concentrations of each chemotherapeutic agent in culture media. Cells that overexpress P-glycoprotein (MCF7/Adr and CLI/Pac), breast cancer-resistant protein (MCF7/TPT and CLI/Tpt), and MDR-associated protein 1 (MCF7/Vp) were used in this study. All resistant mutants were insensitive to gefitinib. Gefitinib (0.3-3 μmol/L) added to culture media had no effect on IC50 values of paclitaxel, topotecan, doxorubicin, or etoposide in wild-type MCF7 or CLI cells. In contrast, these concentrations of gefitinib caused a dose-dependent reversal of resistance to paclitaxel in CLI/Pac cells, to doxorubicin in MCF7/ADR cells, and to topotecan in CLI/Tpt and MCF7/TPT cells. Gefitinib had no influence on sensitivity to etoposide in MDR-associated protein1 overexpressing MCF7/VP cells. Topotecan efflux was inhibited and accumulation was partially restored in CLI/Tpt and MCF7/TPT cells when cells were incubated simultaneously with gefitinib. Our results suggest that the interaction of gefitinib and chemotherapeutic agents does occur in cells expressing one of these two proteins.

UR - http://www.scopus.com/inward/record.url?scp=23044449295&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23044449295&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-05-0641

DO - 10.1158/0008-5472.CAN-05-0641

M3 - Article

C2 - 16061679

AN - SCOPUS:23044449295

VL - 65

SP - 6943

EP - 6949

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 15

ER -